Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 275 entries
View as:

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

Phase: N/A Priority: Normal
NCT ID: NCT01416987 Org: User:
Start: 08/14/11 End: 05/10/18 Due: 05/10/19

Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01438528 Org: User:
Start: 12/31/11 End: 12/31/15 Due: 12/31/16

A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01251146 Org: User:
Start: 11/30/10 End: 02/29/12 Due: 02/28/13

Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria

Phase: N/A Priority: Normal
NCT ID: NCT01732471 Org: User:
Start: 11/30/12 End: 10/31/13 Due: 10/31/14

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00367484 Org: User:
Start: 05/31/04 End: 01/31/06 Due: 01/31/07

TRUST Study: Raptiva ® in Hand & Foot Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00739882 Org: User:
Start: 04/30/08 End: 06/30/09 Due: 06/30/10

To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01079975 Org: User:
Start: 08/31/08 End: 07/31/12 Due: 07/31/13

To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01080040 Org: User:
Start: 08/31/08 End: 03/31/13 Due: 03/31/14

A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization

Phase: N/A Priority: Normal
NCT ID: NCT01185015 Org: User:
Start: 01/31/11 End: - Due: -

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT01142869 Org: User:
Start: 12/31/09 End: 08/05/14 Due: 08/05/15

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Phase: N/A Priority: Normal
NCT ID: NCT01080066 Org: User:
Start: 09/30/10 End: 12/31/13 Due: 12/31/14

A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)

Phase: N/A Priority: Normal
NCT ID: NCT01746862 Org: User:
Start: 12/31/12 End: 03/31/15 Due: 03/31/16

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East

Phase: N/A Priority: Normal
NCT ID: NCT02015286 Org: User:
Start: 03/31/14 End: 12/31/15 Due: 12/31/16

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)

Phase: N/A Priority: Normal
NCT ID: NCT02015273 Org: User:
Start: 02/28/14 End: 12/31/15 Due: 12/31/16

Low-dose Gonal-f® in Ovulation Induction

Phase: N/A Priority: Normal
NCT ID: NCT01871532 Org: User:
Start: 07/31/13 End: 11/30/14 Due: 11/30/15

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00678535 Org: User:
Start: 06/30/08 End: 02/28/13 Due: 02/28/14

Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)

Phase: N/A Priority: Normal
NCT ID: NCT02047227 Org: User:
Start: 01/31/14 End: 08/31/15 Due: 08/31/16

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00960115 Org: User:
Start: 12/31/08 End: 06/30/15 Due: 06/30/16

An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

Phase: N/A Priority: Normal
NCT ID: NCT01080729 Org: User:
Start: 02/28/09 End: 02/28/10 Due: 02/28/11

Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period

Phase: N/A Priority: Normal
NCT ID: NCT01082328 Org: User:
Start: 05/31/10 End: 05/31/12 Due: 05/31/13

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Phase: N/A Priority: Normal
NCT ID: NCT03387046 Org: User:
Start: 03/26/18 End: 01/11/19 Due: 01/11/20

A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01142583 Org: User:
Start: 07/31/06 End: 08/31/09 Due: 08/31/10

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France

Phase: N/A Priority: Normal
NCT ID: NCT01291394 Org: User:
Start: 01/31/11 End: 12/31/15 Due: 12/31/16

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00287079 Org: User:
Start: 10/31/05 End: 11/30/08 Due: 11/30/09

Tecemotide (L-BLP25) in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01507103 Org: User:
Start: 02/29/12 End: 06/30/14 Due: 06/30/15